TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02575612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum-assisted biopsy
Description: Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (\> 50 ultrasound guided minimal invasive biopsies per year, \> 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
Study: NCT00089492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Background ARVs
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 180mg sc once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid for 48 weeks
Study: NCT01172028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere (Docetaxel)
Description: Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta (Pemetrexed)
Description: ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
Study: NCT04256850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Teaches acceptance, mindfulness, and values-based skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation (SR)
Description: Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
Study: NCT02482311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 1775
Description: AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food.
Study: NCT03545672

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
Study: NCT04573855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 immunoglobulin
Description: Treatment with Anti-SARS-CoV-2 immunoglobulin
Study: NCT03528317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate day fasting
Description: Alternate day fasting with a high protein diet
Study: NCT02772029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT01912014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support and counselling
Study: NCT00377910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aethoxysclerol
Description: 2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
Study: NCT01236313

Intervention type: PROCEDURE
Intervention: TEE report
Description: Information will be collected during cardiac surgery.
Study: NCT00318123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kivexa
Description: abacavir 600mg + lamivudine 300mg in one tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kivexa
Description: abacavir 600mg + lamivudine 300mg in one tablet QD
Study: NCT00007683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin titrated to an INR of 2.5-3.0
Description: anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75
Description: (an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
Study: NCT04099147

Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational study. No intervention is planned outside of usual clinical practice.

Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational study. No intervention is planned outside of usual clinical practice.
Study: NCT01116115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InFat™ based infant formula
Description: High sn-2 palmitic acid oil based infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vegetable oil based infant formula
Description: Standard vegetable oil based infant formula
Study: NCT01541631

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40mg/kgBWT Albendazole - 400mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40mg/kgBWT Albendazole - 400mg once
Study: NCT04256525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Description: 10mg orally per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: 100mg orally per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecule heparin
Description: 0.4ml per day subcutaneous injection
Study: NCT02862574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous injection once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally weekly as part of the participant's current treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally weekly as part of the participant's current treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally weekly as part of the participant's current treatment regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally weekly as part of the participant's current treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Study: NCT01238510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent technique: Provisional fKBT
Description: Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only
Study: NCT01429077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Study: NCT04205578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dl-3-n-butylphthalide (NBP)
Description: 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution
Description: 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
Study: NCT04090905

Intervention type: OTHER
Intervention: Standard clinical monitoring
Description: Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.

Intervention type: OTHER
Intervention: Standard clinical monitoring
Description: Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter monitoring
Description: Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
Study: NCT03741725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pay-it-forward
Description: Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pay-what-you-want
Description: Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
Study: NCT00974051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Oral (2.5mg) one time administration at 9:00pm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% basal insulin reduction
Description: Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
Study: NCT01541631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40MG/KG ONCE Albendazole - 400mg once

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40MG/KG ONCE Albendazole - 400mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
Study: NCT03809312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin / Clavulanic acid 875mg / 125mg
Description: Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
Study: NCT00974051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No treatment is given for the study. This arm is for comparison with the two intervention arms.
Study: NCT03822871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1403
Description: Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1403
Description: Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
Study: NCT03809312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin / Clavulanic acid 875mg / 125mg
Description: Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos BID x 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos BID x 10 days
Study: NCT03822871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
Study: NCT01042197

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
Study: NCT03822871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
Study: NCT02652312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
Study: NCT01042197

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Study: NCT02652312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 0.15 mg/kg intravenous (IV) will be given as a pre-medication

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 0.15 mg/kg intravenous (IV) will be given as a pre-medication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 1.5 μg/kg intraoperative

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: 1.5 μg/kg intraoperative

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: 0.5 mg/kg IV for endotracheal intubation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: 0.5 mg/kg IV for endotracheal intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: 1 mg/kg for postoperative analgesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac sodium
Description: 1 mg/kg for postoperative analgesia
Study: NCT01042197

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Study: NCT02652312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: 1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: desflurane
Description: 1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
Study: NCT01650818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy (Stretching/Range-of-motion)
Description: Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
Study: NCT01193140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Dose orally twice daily for 7 days, consecutively, every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Dose orally once daily for 5 days, consecutively, every cycle
Study: NCT01408667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRC150094
Description: 50 mg Tablets once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets once daily
Study: NCT02862574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Study: NCT00289185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02D
Description: 3-dose intramuscular injection in the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B®
Description: 3-dose intramuscular injection in the thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.
Study: NCT02862574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNF Inhibitor
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Study: NCT03759496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
Study: NCT05073965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects were assigned to receive a 1000IU vitamin D supplement dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject were assigned to receive a placebo
Study: NCT01129180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC
Study: NCT03276182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipiview 2
Description: Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
Study: NCT03981874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephonic interview
Description: Telephonic interview
Study: NCT02068144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Extract
Description: Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
Study: NCT01129180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
Study: NCT01461512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate administration
Description: heme arginate 1 mg/kg body weight 24 hours prior to ischemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: NaCl isotonic
Study: NCT01717703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cola